Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 196.91% and Operating profit at 48.07% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 0.29%, it has a very expensive valuation with a 8.35 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,013 Million (Large Cap)
2,847.00
NA
0.00%
-0.33
4.42%
7.70
Revenue and Profits:
Net Sales:
74 Million
(Quarterly Results - Dec 2025)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.1%
0%
20.1%
6 Months
-1.8%
0%
-1.8%
1 Year
43.73%
0%
43.73%
2 Years
69.65%
0%
69.65%
3 Years
-6.51%
0%
-6.51%
4 Years
106.87%
0%
106.87%
5 Years
0%
0%
0.0%
Shanghai Yizhong Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
196.91%
EBIT Growth (5y)
48.07%
EBIT to Interest (avg)
80.83
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.18
Tax Ratio
39.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
32.26%
ROE (avg)
7.02%
Valuation key factors
Factor
Value
P/E Ratio
2847
Industry P/E
Price to Book Value
8.35
EV to EBIT
-972.78
EV to EBITDA
11520.41
EV to Capital Employed
13.06
EV to Sales
54.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.34%
ROE (Latest)
0.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
73.90
82.80
-10.75%
Operating Profit (PBDIT) excl Other Income
11.70
4.10
185.37%
Interest
0.00
0.00
Exceptional Items
0.00
0.90
-100.00%
Consolidate Net Profit
13.50
12.70
6.30%
Operating Profit Margin (Excl OI)
158.10%
48.90%
10.92%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -10.75% vs -7.28% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 6.30% vs -46.64% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
317.10
172.50
83.83%
Operating Profit (PBDIT) excl Other Income
62.10
-4.10
1,614.63%
Interest
0.00
0.80
-100.00%
Exceptional Items
0.00
2.80
-100.00%
Consolidate Net Profit
64.10
7.00
815.71%
Operating Profit Margin (Excl OI)
195.80%
-92.80%
28.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 83.83% vs -51.95% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 815.71% vs -95.67% in Dec 2024
About Shanghai Yizhong Pharmaceutical Co., Ltd. 
Shanghai Yizhong Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






